Objectives: Pan-susceptible Pseudomonas aeruginosa (PSPA) clinical isolates carrying an OprD with loop 7 shortening (the group-1A allele) were found to rapidly develop carbapenem resistance under continuous selection pressure. We further studied whether OprD polymorphisms are associated with the potential to develop carbapenem resistance.
Introduction
Pseudomonas aeruginosa has become one of the leading causes of healthcare-associated infection, particularly in patients with cystic fibrosis. 1 Carbapenems, such as imipenem, meropenem and doripenem, continue to be important antimicrobials for treating infections caused by MDR P. aeruginosa. However, the emergence of carbapenem-resistant P. aeruginosa (CRPA) has become a serious concern worldwide. Two major mechanisms are associated with the development of carbapenem resistance: the intrinsic mutation of chromosomally encoded resistance-related genes, and the acquisition of genes encoding antibiotic-inactivating enzymes. [2] [3] [4] We previously demonstrated that an intrinsic mutational mechanism, particularly the decreased expression of oprD-encoding porins, is the most frequent mechanism for the development of carbapenem resistance in P. aeruginosa, as demonstrated in other studies. [4] [5] [6] [7] [8] In contrast, carbapenemase genes were relatively less frequently identified in a non-outbreak setting. 9 OprD is a specific P. aeruginosa outer-membrane porin that can facilitate the diffusion of specific substrates, such as basic amino acids and carbapenem antibiotics (particularly imipenem and, presumably, meropenem). 10, 11 OprD consists of transmembrane segments interconnected by seven short turns on the periplasmic side V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
and eight longer flexible loops on the external surface. Among them, loop 2 (L2) and L3 are associated with the binding and passage of imipenem through OprD, respectively. 11, 12 OprD-mediated carbapenem resistance can be achieved by the downregulation of oprD expression or the inactivation of this porin through a frameshift by the insertion/deletion mutation and/or a premature stop codon. 13, 14 Disruptions of oprD by various insertion sequence elements leading to the inactivation of porins have also been reported elsewhere. 15, 16 Furthermore, no apparent 'hot spot(s)' could be located for such mutational changes, judging from the previously reported polymorphisms observed in CRPA isolates. 13, 17 In a matched-pair study, we recently found that a group of pan-susceptible P. aeruginosa (PSPA) clinical isolates can rapidly evolve into carbapenem resistant-only P. aeruginosa (CROPA) under continuous carbapenem selection pressure. Eight of the 10 CROPA pan-susceptible counterparts carried a specific oprD group-1A allele (L7 shortening), whereas the remaining two PSPA isolates carried full-length oprD with amino acid polymorphisms. Despite this difference, the inactivation of OprD by various insertion/deletion mutations, which led to a frameshift and a premature stop codon, was found in all of these CROPA isolates. 18 In the present study we continued to investigate the effect of these polymorphisms observed in PSPA isolates on the development of carbapenem resistance.
Materials and methods

Ethics
The present study aimed to characterize P. aeruginosa isolates using molecular methods. A total of 126 non-repetitive PSPA blood isolates were retrieved retrospectively from the Bacteria Bank hosted in the Department of Laboratory Medicine, Chang Gung Memorial Hospital, Linkou. Clinical information of the patients was neither available nor required in this study. Because all microbial cultures had been ordered by physicians due to their necessity for clinical management, the patient's informed consent was not required and was thus not collected. The study design and procedure were approved by the Institutional Review Board of the Chang Gung Memorial Hospital, Linkou.
Setting, bacterial isolates and antimicrobial susceptibility testing
Chang Gung Memorial Hospital at Linkou is a university-affiliated medical centre with a 3700 bed capacity in Taiwan. The 126 PSPA isolates were identified by standard methods at this hospital during 2012, and their susceptibilities to antimicrobial agents were determined by a standard disc diffusion method according to the CLSI guidelines. 19 These PSPA isolates were susceptible to all tested antimicrobial agents: amikacin, gentamicin, ceftazidime, aztreonam, ciprofloxacin, cefepime, piperacillin, piperacillin/tazobactam, meropenem and imipenem.
Non-susceptible variants were first selected by the disc diffusion method according to the CLSI guidelines. 19 Their MICs of carbapenems (imipenem, meropenem, and doripenem) were subsequently determined using Etest strips according to the manufacturer's (bioMérieux) guidelines.
DNA sequencing
A primer set, OprD-F (5 0 -CGCCGACAAGAAGAACTAGC-3 0 ) and OprD-R (5 0 -GTCGATTACAGGATCGACAG-3 0 ), was used for oprD PCR/sequencing. An additional primer, OprD-F2 (5 0 -GCCGACCACCGTCAAATCG-3 0 ), was specifically used with OprD-R to detect the shortening in the L7 region of the oprD. The polymorphisms of the OprD amino acid sequences identified among the PSPA isolates were categorized into different STs using P. aeruginosa strain PAO1 as the control strain.
Selection of carbapenem resistance by the disc diffusion method
Selection for mutation-driven carbapenem resistance was performed by placing an imipenem, meropenem or doripenem disc on a Mueller-Hinton agar plate inoculated with the indicated P. aeruginosa isolates. The procedure was the same as the standard disc diffusion method for antimicrobial susceptibility testing. 19 After overnight incubation, the bacterial colonies that had grown within the inhibition zone, if any, or those that had grown at the margin of the zone were selected, and the same disc diffusion method was performed. The diameters of the inhibition zones were recorded for each passaging event and compared.
Site-directed mutagenesis of oprD
To examine the effect of any particular polymorphism, site-directed mutagenesis of oprD was performed by introducing the polymorphisms of interest through the pEX18Tc system into P. aeruginosa strain PAO1 according to methods described elsewhere. 20 The plasmid construct was prepared by cloning the target DNA fragment using PAO1 genomic DNA as the template. Plasmids with the DNA fragment of interest were then mobilized from the host Escherichia coli S1-1 to P. aeruginosa PAO1 via conjugation. Transconjugants were selected on LB agar plates containing tetracycline (50 mg/L) and chloramphenicol (5 mg/L; counterselection of E. coli). The tetracycline-resistant colonies were further selected by their sucrose resistance on LB agar plates containing 10% (w/v) sucrose. The sucrose-resistant colonies were screened for the oprD polymorphisms of interest after homologous recombination using PCR and DNA sequencing. The transconjugants with oprD L7 shortening or the F170L polymorphism were named PAO1-SL7 and PAO1-F170L, respectively.
Quantitative real-time RT-PCR (qRT-PCR)
The expression levels of oprD, mexA and ampC were determined by qRT-PCR according to previously described methods. 21 All amplifications were performed in triplicate. The mRNA level was normalized to that of the housekeeping gene rpsL using the Pfaffl equation. 22 The results were presented as fold-change expression levels relative to that of the WT strain PAO1. The change in gene expression level was considered to be significant when the ratio was .2.5 or ,0.4 for oprD, .3 for mexA and .10 for ampC.
23,24
Genomic fingerprinting
Genomic fingerprinting was performed by PFGE and MLST. A PFGE analysis of SpeI-digested DNA fragments was performed as described elsewhere. 18 The 10 paired isolates were further subjected to an MLST assay by sequencing seven housekeeping genes according to methods described previously. 18 The allelic profiles of each gene and the subsequent STs were determined by referring to the MLST database (http://pubmlst.org/paerugi nosa/).
Results
Association between OprD STs and the potential to develop carbapenem resistance
To study whether the OprD polymorphisms were associated with the potential for carbapenem resistance development, OprD amino acid STs among 126 PSPA clinical isolates were analysed Shu et al.
( Table 1 ). The group-1A allele was identified in 48 (38.1%) of the isolates. The remaining 78 isolates were further categorized into three major and four minor STs. Two of the three major STs, C1 (n " 21, 16.7%) and C2 (n " 39, 31.0%), had been reported previously. 25 The isolates sharing common polymorphisms in L2, L3 and L6 were defined as subtypes of C2. Fourteen (11.1%) isolates belonged to the PAO1 type. The remaining four isolates were categorized as types D-G, but polymorphisms identified in types D, E and G were also observed in type C2 or its subtypes (Table 1) .
Clonality within each major ST had been excluded by the diverse PFGE patterns demonstrated in 54 randomly selected isolates (7, 10, 18 and 12 isolates from types PAO1, C1, C2 and group-1A, respectively, and one each from the seven remaining types; Figure S1 , available as Supplementary data at JAC Online). Among them, eight isolates (three and five isolates from types C1 and C2, respectively) had also been analysed by MLST, and none of them shared the same MLST ( Figure S1 ).
One isolate from each OprD ST/subtype, except for isolates carrying the group-1A allele that had been demonstrated previously, was selected as the representative and was subjected to the selection of resistant variants by various carbapenems. 18 Compared with strain PAO1, the isolates belonging to different STs also showed various carbapenem susceptibilities before selection. For example, the isolates belonging to type C2 or C2-2 showed hypersensitivity to all of the carbapenems tested in this study, whereas the isolates belonging to type D or G were less susceptible to both meropenem and doripenem ( Figure 1 ).
After serial passages in the presence of carbapenems, no resistance variants were found in isolates belonging to the PAO1 type, even at up to 15 passages (Figure 1 ). For the other STs, although resistance variants were generated, the number of passages required for the development of carbapenem resistance varied greatly among isolates from different STs. Under imipenem selection pressure, isolates belonging to type C1 rapidly developed imipenem resistance in three passages, whereas isolates of type D required 11 passages to become resistant (Figure 1a) . Upon meropenem exposure, isolates belonging to type C2-1 first achieved the resistance criteria after three passages, whereas those from type D did not become resistant until after nine passages (Figure 1b) . Under doripenem pressure, isolates of type C2-1 were the first to achieve the resistance criteria after five passages. However, isolates of types C1, C2-3 or F did not achieve the doripenem resistance criteria throughout the study period (after 15 passages; Figure 1c) . Moreover, differences between the carbapenem compounds were observed. Except for isolates of the PAO1 type, the average number of passages required to achieve the resistance criteria for imipenem and meropenem was 7.1 and 6.9, respectively. However, for those with doripenem resistance, the average number of passages required to achieve this was 8.4, much greater than that found for imipenem or meropenem (Figure 1 ).
Effect of L7 shortening and the change in codon 170 in OprD on the development of carbapenem resistance A common polymorphism at codon 170 (PAO1 strains, phenylalanine; others, leucine) in L3 of OprD was found in all PSPA isolates, except for isolates of types PAO1, F and G (Table 1) . We then further investigated the effect of the F170L change and the 
Carbapenem resistance associated with OprD polymorphisms JAC specific shortening (group-1A allele) in OprD L7 on the development of carbapenem resistance. Two mutant strains, PAO1-SL7 and PAO1-F170L, were specifically generated by site-directed mutagenesis. Together with the parent strain PAO1, the mutants were subjected to continuous challenge by various carbapenems. As shown in Figure 2 , strain PAO1 remained susceptible throughout the experimental period, even up to 15 passages, but resistance was soon observed in mutants carrying either the oprD group-1A allele (PAO1-SL7) or the F170L polymorphism (PAO1-F170L). However, more passages were required for the two mutant strains to develop resistance to either meropenem or doripenem. The numbers of passages required to achieve the imipenem resistance Shu et al.
criteria were three and seven, respectively, for strains PAO1-F170L and -SL7; however, six and nine passages were required for strains PAO1-F170L and PAO1-SL7, respectively, to reach resistance to both meropenem and doripenem. Sequence analysis of one representative isolate from each passage revealed that oprD remained unchanged before the resistant variants were found. However, an 8 bp insertion at nt 596-603, leading to a frameshift and a stop codon at amino acid 222, was found among the imipenem-resistant variants of PAO1-SL7 obtained after seven passages and thereafter. Similarly, a 1 bp deletion at nt 140, resulting in a frameshift and a stop codon at amino acid 64, was found among the imipenem-resistant variants of PAO1-F170L after four passages and thereafter. Among the resistant variants generated by meropenem challenge, a 5 bp deletion at nt 903-907, which led to a premature stop codon at amino acid 302, was found in PAO1-SL7 after nine passages and thereafter. A single point mutation, G831A, which led to a premature stop codon at amino acid 277, was found in PAO1-F170L after nine passages and thereafter.
Cross-resistance between imipenem and meropenem was further examined among the resistant variants. The imipenem MICs for the 10th passage of the imipenem-selected PAO1-SL7 and PAO1-F170L resistant variants were both .32 mg/L, whereas the meropenem MICs for these two strains were 3 and 2 mg/L, respectively. However, the MICs of imipenem and meropenem for the 12th passage of the meropenem-selected PAO1-SL7 and PAO1-F170L resistant variants were both .32 mg/L.
Activation of intrinsic resistance mechanisms among the various STs of OprD
Before the loss-of-function mutation in oprD was detected, a reduction in the inhibition zone size had been observed in both mutant strains, i.e. PAO1-SL7 and PAO1-F170L (Figure 2 ). Further examination of the oprD expression level revealed a significant decrease among non-susceptible isolates derived from strains PAO1-SL7 and PAO1-F170L. There was no significant difference in oprD expression among PAO1 isolates from each of the passages. Compared with the PAO1 control strain, oprD expression in PAO1-SL7 decreased to 0.22-fold at the sixth passage and further dropped to 0.05-fold at the 11th passage. The expression level of oprD in PAO1-F170L decreased to 0.55-fold (0.40-fold in comparison with F170L parental strain) at the fourth passage and thereafter. To confirm that oprD expression may be reduced before the occurrence of any mutation in the oprD, qRT-PCR was performed on strains PAO1, PAO1-SL7 and PAO1-F170L during a short period of imipenem challenge at sub-optimal concentrations (0.5-fold MIC). The expression level of oprD remained steady in strain PAO1 for up to 3 h posttreatment. However, in the two mutant strains, oprD expression reduced significantly from 75% of that in strain PAO1 to 0.3-fold in PAO1-SL7 and 0.2-fold in PAO1-F170L upon imipenem treatment. The lack of DNA substitutions in oprD among those three strains was confirmed by sequencing.
We further investigated whether other intrinsically mutational mechanisms, such as overexpression of mexAB (encoding efflux pumps) or ampC (encoding cephalosporinase), may have contributed to the development of the observed carbapenem resistance. Under continuous imipenem pressure, the expression level of either mexA or ampC did not change significantly among the three strains selected from different passages ( Figure S2a ). Interestingly, a significant increase in mexA (20.5-fold) and ampC (51.7-fold) expression was observed in PAO1-F170L and PAO1-SL7, respectively, after the oprD loss-of-function mutation was detected under continued meropenem pressure ( Figure S2b) .
A polar effect is found in organisms containing polycistronic mRNA. The orientation of oprD is opposite to the two ORFs PA0957 and PA0959 nearby and their transcription was not affected by imipenem treatment (data not shown). Therefore, a polar effect can be ruled out after the allelic replacement of oprD.
Discussion
Clinically, loss-of-function mutations in oprD, which are caused by premature truncation through frameshifts that occur either by insertion or deletion mutations, are always found among CRPA clinical isolates. 13, 14, 26, 27 Through oprD sequence analysis of 126 PSPA isolates, we found that 97% of the isolates could be categorized into four major STs (Table 1 ). All isolates, except those belonging to the group-1A type, carried a full-length oprD, and no premature stop codons were found. We speculate that various oprD mutations observed in the CRPA isolates might be a post-selection effect due to the carbapenem challenge in clinical settings. We further demonstrated that all but the PAO1-type isolates could rapidly develop carbapenem resistance through continuous carbapenem treatment (Figure 1) , which was also found among isolates carrying the oprD group-1A allele. 18 In other words, 90% of the PSPA clinical isolates possess the potential to rapidly become CRPA under carbapenem selection pressure. This is in agreement with previous findings that exposure to carbapenems was the only risk factor for developing CROPA bacteraemia upon infection by PSPA, 28 and that OprD loss was highly associated with the frequent use of meropenem. 7 Most of the frequent amino acid substitutions shown in Table 1 have been reported elsewhere. 13 However, the role of these common polymorphisms in carbapenem resistance development has not been well addressed. Except for the PAO1 type, all of the other OprD polymorphisms identified here were present on different external loops (Table 1) . Isolates carrying the oprD group-1A allele (L7 shortening) have been shown to open the porin channel sufficiently, leading to an increase in penetration by carbapenems, in particular meropenem. 29 Through the analysis of OprD amino acid polymorphisms, we found a common point substitution at codon 170. In fact, the polymorphisms of Leu170 and L7 shortening were found in many published OprD sequences in the GenBank database as well as in clinical isolates reported elsewhere. 13, 25 Further molecular manipulation studies demonstrated that either L7 shortening or the F170L mutation alone is able to determine the potential to develop carbapenem resistance in P. aeruginosa. The F170L mutation is located on L3, which, together with L2, is associated with imipenem binding and passage through the porin. 12 However, both phenylalanine and leucine are characterized as being in the same amino acid group with a hydrophobic side chain. The mechanism underlying the change from phenylalanine to leucine at codon 170 in the development of carbapenem resistance remains to be elucidated.
We also identified two novel single point mutations, G265S (type G) and R310S (type F) that were associated with the development of carbapenem resistance under selection pressure (Figure 1 Carbapenem resistance associated with OprD polymorphisms JAC and Table 1 ). Owing to the rarity of the two polymorphisms, no further molecular manipulation studies were performed. Therefore, we could not exclude the possibility that some other mechanisms may have been involved. The two amino acids were located in L5 and L6. Mutations in L5 could result in hypersusceptibility to b-lactams and other antibiotics, whereas the mutations in L6 did not have similar effects. 30 Reduced oprD expression has been reported among carbapenemase-negative, carbapenem-non-susceptible clinical isolates carrying full-length oprD genes. 13, 31 Specific single amino acid substitutions in OprD could lead to reduced expression of OprD and increased MICs of carbapenems. 17, 31 In the present study, the size of the inhibition zones reduced gradually during the selection period; however, before the zone sizes reached the range for resistance, no mutations were found in the oprD genes of both strain PAO1-SL7 and strain PAO1-F170L. Subsequent qRT-PCR experiments demonstrated that the observed reduced susceptibility was due to the decrease in oprD expression. A lower basal level of oprD expression and thus a slight increase in imipenem MIC were also observed in the two mutant strains PAO1-SL7 and PAO1-F170L. Thus, the potential to trigger intrinsic mechanisms, such as reduced oprD gene expression, of carbapenem resistance appears to be associated with OprD polymorphisms.
Other intrinsic mechanisms for carbapenem resistance, such as the overexpression of mexAB and ampC, were also investigated. The intrinsic imipenem resistance mechanism achieved mainly through the loss of OprD and overproduction of MexAB efflux pumps may also contribute to the resistance to meropenem. 2 The overexpression of some AmpCs with broadened hydrolytic activity towards imipenem and extended-spectrum cephalosporinases (ESACs) has also been identified. 32 However, it has been assumed that AmpC overproduction alone may not significantly alter carbapenem susceptibility in P. aeruginosa.
3 These mechanisms were not triggered in strain PAO1 upon exposure to either imipenem or meropenem. Significant increases in the expression of either mexA or ampC were also not observed in strains PAO1-SL7 and F170L upon exposure to imipenem, confirming that these two mechanisms make little contribution to the imipenem resistance ( Figure S2 ). Interestingly, upon exposure to meropenem a significant increase in the expression of mexA in PAO1-F170L and in that of ampC in PAO1-SL7 was observed after the loss-of-function mutation in oprD was detected ( Figure S2 ). These results may further explain our observations that susceptibility to meropenem (and possibly doripenem also) continued to decrease gradually even when truncation mutations of oprD had occurred (Figure 2 ). Our results suggest that OprD polymorphisms play an import role in carbapenem resistance in association with different intrinsic mechanisms. Reduction or loss of OprD alone may not completely overcome selection pressure from meropenem or doripenem, but the porin may be essential, in association with other mechanisms, for the exertion of maximum resistance to meropenem or doripenem. In addition to OprD reduction or loss, which of the secondary intrinsic mechanism is activated may be related to the OprD ST; e.g. the overexpression of mexA may be associated with F170L polymorphism under meropenem pressure.
The susceptibility of PAO1 to carbapenems did not change at all throughout the experimental period, as demonstrated by qRT-PCR analysis showing that the above intrinsic mechanisms were not triggered. To our knowledge, this finding has never been reported.
Understanding the underlying mechanisms of this phenomenon may help to formulate a better strategy for overcoming carbapenem resistance in P. aeruginosa.
In conclusion, the majority of clinical PSPA isolates are able to develop carbapenem resistance. OprD polymorphisms, particularly those resulting in L7 shortening and the variation in codon 170, are closely associated with the potential of PSPA isolates to develop carbapenem resistance. When facing carbapenem pressure, PSPA may first activate intrinsic mechanisms, such as reducing porin expression. If such changes do not overcome the antibiotic pressure, a further oprD loss-of-function mutation may result. If necessary, the combined use of carbapenems with other classes of antibiotics may lead to a better treatment outcome than when carbapenems are used alone.
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